ZURICH, June 17 (Reuters) – Actelion could attract
potential bidders after strong results for the Swiss biotech
company’s new heart and lung drug, Deutsche Bank analysts said
on Tuesday, as a wave of deals sweeps through the healthcare
Europe’s biggest biotech company has been touted as a
takeover candidate in the past and the stellar data could
reassure potential investors that the firm’s long-term growth
prospects are on course.
ZURICH, June 16 (Reuters) – Actelion Ltd said its
experimental heart and lung drug Selexipag met its primary goal
in a late-stage study, giving the Swiss biotech company a
potential second big seller to replenish its product pipeline.
Selexipag is the third drug from Actelion to treat pulmonary
arterial hypertension (PAH), a progressively worsening condition
characterised by abnormally high blood pressure in the arteries
of the lungs. The cause is unknown and the disease has no cure.
ZURICH (Reuters) – The Swiss government is weighing new measures to cool demand in the housing market out of fear that Switzerland’s high levels of household debt could provoke a real estate crash if the economy went into recession, a senior finance official told Reuters.
The International Monetary Fund has sounded alarm bells about escalating house prices around the world and last month urged Switzerland to implement more aggressive policies to dampen demand for mortgages.
ZURICH (Reuters) – Roche is betting the same tools that made it the world’s largest producer of cancer drugs will help it tackle the growing public health crisis of antibiotic resistance as regulators and politicians encourage fresh research.
The Swiss drugmaker used its expertise in in vitro diagnostic tests to develop highly-targeted cancer medicines. Now it believes it can use those same skills to find out quickly which bugs cause which infections, and help doctors kill them.
SHANGHAI/ZURICH, May 22 (Reuters) – Swiss drugmaker Roche
Holding AG said it had been visited by a unit of
China’s anti-trust regulator – a move that comes amid a widening
crackdown on corruption and high prices in the country’s
However, it was not immediately clear what was behind the
Roche said its offices in the eastern city of Hangzhou had
been visited by a unit of the State Administration for Industry
and Commerce (SAIC). The SAIC usually takes the lead in cases of
bribery and corruption.
ZURICH, May 18 (Reuters) – Swiss voters on Sunday rejected
proposals to introduce the world’s highest minimum wage and
spend $3.5 billion buying new Gripen fighter jets from Saab
About 76 percent of voters in the wealthy nation dismissed
the proposal made by Swiss union SGB and backed by the Socialist
and Green parties for a minimum wage of 22 Swiss francs ($25)
per hour, final results showed.
ZURICH, May 13 (Reuters) – Gene Signal is in talks with
potential partners to help develop its new treatment for a
leading cause of blindness in the elderly, the biotech firm’s
chief executive said on Tuesday.
Privately-held Gene Signal is looking to muscle in on the
lucrative market for treating wet age-related macular
degeneration (AMD) currently dominated by Roche’s
Lucentis and Regeneron’s Eylea.
ZURICH/FRANKFURT (Reuters) – Swiss Re (SRENH.VX: Quote, Profile, Research, Stock Buzz) and Hannover Re (HNRGn.DE: Quote, Profile, Research, Stock Buzz), the world’s no. 2 and 3 reinsurers, said they saw lower prices in natural disaster reinsurance and April renewals, as they beat profit expectations in the first quarter.
Fewer serious natural disasters, as well as competition from pension funds pouring money into the reinsurance industry, have crimped the pricing power of reinsurers, which help primary insurers cover the cost of major damage claims in return for part of the premiums.
ZURICH, April 30 (Reuters) – Straumann Holding AG,
the world’s largest maker of dental implants, posted a 2.9
percent rise in sales in the first quarter as it started to reap
the benefit of a new pricing strategy.
The premium dental implant market has shown tentative signs
of a turnaround in recent quarters, after the financial crisis
made consumers in developed countries postpone or scrap
non-urgent treatment and trade down to cheaper brands.
ZURICH, April 29 (Reuters) – The deal-making frenzy sweeping
through the healthcare industry should continue apace in 2014,
as companies look to stock up new drug pipelines, bolster
existing businesses and diversify into new areas, Moody’s
Investors Service said on Tuesday.
Deals totalling more than $153 billion have been struck in
the sector so far this year, the highest year-to-date level
since Thomson Reuters began tracking such data.